Clario announces investment in new translation service technology to reduce eCOA study start-up times and increase global patient access to clinical trials
Leading clinical trial endpoint technology provider sets ambitious targets to reduce translation timelines by 20-30% with investment in new technology and processes
PHILADELPHIA, PA – August 12, 2022 – Clario, a technology company that delivers the leading endpoint technology solutions for decentralized (DCT), hybrid and site-based clinical trials, today announced an investment in new translation service technology – the Clario Translation Workbench – to reduce translation times by 20-30% which will speed up eCOA study start-up and increase global patient access to clinical trials.
“Our clients need to deploy studies in multiple countries and ensure patients have access to accurate and timely translations of their electronic clinical outcomes assessments. This is critical to a successful study. With Clario’s global reach and this investment in technology and process to reduce translation times, we can help increase patient access and speed up overall study set-up times,” said Andy Cooper, EVP eCOA & Trial Enablement.
The Translation Workbench will:
- Use new technology to reduce the time spent in communications between the Translation vendor and Clario
- Reduce the burdensome processes associated with generating accurate screenshots and translations of the related screens on eCOA applications
- Reduce defects, and minimize human error through investment in automation and a new centralized data platform
Clients need reliable translation services to launch studies in multiple countries and reach a diverse patient population. However, they often face delays and challenges with the technical nature of the work. A key focus of the investment is to reduce the number of manual steps often needed in the technical and complex process of delivering accurate translations. Clario’s new Translation Workbench technology has been developed and released to directly address those problems.
About Clario
Clario is a leading healthcare research and technology company that generates better clinical evidence for our pharmaceutical, biotech, and medical device partners. We have the only evidence generation platform in the industry that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints.
Clario’s global team of science, technology, and operational experts have helped deliver over 26,000 trials and contributed to over 800 regulatory approvals in more than 100 countries. For more than 50 years, we have delivered deep scientific expertise and the most comprehensive endpoint technologies to help transform lives around the world.
For more information, go to Clario.com or follow us on LinkedIn and Twitter.
Clario Media Contact
Alexis Navratil
Communications Manager
[email protected]